Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.48 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | SMO | Q99835 | 2/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25839464 | 0.85 | KCNH2 (0.48) | ALDH1A1NPSR1RECQLKCNH2TP53 | |
| SCHEMBL25844474 | 0.82 | L3MBTL1 (0.47) | ALDH1A1LMNA | |
| SCHEMBL23446066 | 0.81 | JAK3 (0.45) | TP53LMNASMOTHRB | |
| SCHEMBL23544826 | 0.79 | ALDH1A1 (0.44) | ALDH1A1NPSR1RECQLKCNH2NOTUM | |
| SCHEMBL19701981 | 0.79 | ALDH1A1 (0.50) | ALDH1A1NPSR1RECQLLMNANOTUM | |
| SCHEMBL16019525 | 0.77 | NOTUM (0.56) | ALDH1A1NPSR1RECQLKCNH2LMNA | |
| SCHEMBL24721098 | 0.76 | NOTUM (0.52) | ALDH1A1NPSR1RECQLLMNANOTUM | |
| SCHEMBL25840577 | 0.75 | MEN1 (0.55) | KCNH2TP53SMOTHRBMAPT | |
| SCHEMBL25839495 | 0.72 | POLB (0.63) | ALDH1A1NOTUMMAPT | |
| SCHEMBL23544878 | 0.72 | NOTUM (0.46) | ALDH1A1NPSR1RECQLNOTUMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-07-11 | — | — | US | disclosed |
| US-20210188844-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2021-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210188844-A1 | FUSED PYRIMIDINE PYRIDINONE COMPOUNDS AS JAK INHIBITORS | JAK3, JAK1, JAK2 | ALDH1A1 2446/4885NPSR1 3649/4885RECQL 1358/4885 |
| US-11697648-B2 | Fused pyrimidine pyridinone compounds as JAK inhibitors | JAK3, JAK1, JAK2 | ALDH1A1 2446/4885NPSR1 3649/4885RECQL 1358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.